HGF and neoplasm: More recently it was demonstrated that the cMET clinical score was not a statistically significant predictive factor for therapy with BRAF-inhibitor [25], and stromal or parenchymal HGF expression levels did not indicate tumor response to inhibitors of BRAF [23].